Optimal choice of carrier type and drug payload will likely involve both identifying goals of treatment and prioritizing outcome metrics (e.g., local suppression of a specific cytokine such as HIF-1α or control of tumor growth). This evidence concerns the gene HIF1A and neoplasm.